Sign up to save your podcasts
Or
Share Healthcare: ASH 2017's Big Winners And Losers
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Healthcare: ASH 2017's Big Winners And Losers
Celgene and bluebird bio report a stunning success in multiple myeloma, Juno Therapeutics takes it on the chin despite positive data, and Spark Therapeutics suffers in its showdown with BioMarin in hemophilia.
View all episodes
By The Motley FoolCelgene and bluebird bio report a stunning success in multiple myeloma, Juno Therapeutics takes it on the chin despite positive data, and Spark Therapeutics suffers in its showdown with BioMarin in hemophilia.